# 📝 Session - Phase 4: Oncology Protocols

**Date:** 2025-02-05  
**Session Type:** Phase 4 - Oncology Protocols Implementation  
**Status:** ✅ Complete - All 3 Protocols Implemented  
**Version:** 2.21.0

---

## ✅ HOÀN THÀNH TRONG PHIÊN NÀY

### **Phase 4: Oncology Protocols** ✅

**Achievement:** Implemented 3 critical oncology emergency protocols

**New Protocols Added:**
1. ✅ **Tumor Lysis Syndrome Prevention** - `protocols/oncology/tls.py`
2. ✅ **Febrile Neutropenia Management** - `protocols/oncology/febrile_neutropenia.py`
3. ✅ **Hypercalcemia of Malignancy** - `protocols/oncology/hypercalcemia.py`

**Statistics:**
- **Before:** 14 protocols (Emergency, Respiratory, Cardiology, Nephrology, Infectious, Endocrinology)
- **After:** 17 protocols (+3 new protocols)
- **New Specialty:** Oncology (first time)
- **Files Created:** 4 files (3 protocols + 1 __init__.py)
- **Files Modified:** 2 files (protocols/__init__.py, pages/04_📋_Protocols.py)

---

## 📋 CHI TIẾT CÁC PROTOCOLS

### **1. Tumor Lysis Syndrome (TLS) Prevention** ✅

**File:** `protocols/oncology/tls.py`  
**Guideline:** NCCN 2023 Guidelines  
**Lines of Code:** ~400 lines

**Features:**
- ✅ Risk stratification (High, Intermediate, Low risk)
- ✅ Laboratory TLS criteria (≥2 of 4 criteria)
- ✅ Clinical TLS definition
- ✅ Prevention protocols by risk level:
  - High Risk: Rasburicase + aggressive hydration
  - Intermediate Risk: Allopurinol + hydration
  - Low Risk: Hydration ± Allopurinol
- ✅ Hydration protocol (2-3 L/m²/day)
- ✅ Uric acid lowering (Allopurinol vs Rasburicase)
- ✅ Electrolyte management (K⁺, PO₄³⁻, Ca²⁺)
- ✅ Monitoring protocol (frequency by risk level)
- ✅ Treatment of established TLS
- ✅ Special populations (pediatrics, renal failure, heart failure, G6PD deficiency)
- ✅ References (NCCN 2023, UpToDate)

**Key Points:**
- Life-threatening complication of cancer treatment
- Prevention is key (hydration + uric acid lowering)
- Rasburicase for high risk, Allopurinol for intermediate/low risk
- G6PD deficiency = contraindication for Rasburicase
- Monitoring frequency: 6-12h (high risk), 12-24h (intermediate), 24-48h (low risk)

---

### **2. Febrile Neutropenia Management** ✅

**File:** `protocols/oncology/febrile_neutropenia.py`  
**Guideline:** IDSA 2010, ASCO 2018 Guidelines  
**Lines of Code:** ~450 lines

**Features:**
- ✅ Definition (fever ≥38.3°C + ANC <500/µL)
- ✅ MASCC Risk Index calculator (interactive)
- ✅ Risk stratification (High risk <21, Low risk ≥21)
- ✅ Initial evaluation (history, labs, imaging, cultures)
- ✅ Empiric antibiotic therapy:
  - High Risk: Monotherapy (Piperacillin-tazobactam, Cefepime, etc.) or Dual therapy
  - Low Risk: Oral (Ciprofloxacin + Amoxicillin-clavulanate) or IV outpatient
- ✅ Antifungal therapy (Caspofungin, Voriconazole, Amphotericin B)
- ✅ Duration of therapy guidelines
- ✅ Outpatient management (low risk criteria)
- ✅ Special considerations (penicillin allergy, MRSA, ESBL, pneumonia, abdominal source, catheter-related)
- ✅ References (IDSA 2010, ASCO 2018, UpToDate)

**Key Points:**
- Medical emergency - start antibiotics immediately
- Do NOT wait for blood culture results
- MASCC score ≥21 = low risk (may treat outpatient)
- MASCC score <21 = high risk (hospitalize)
- Empiric antifungal if fever >4-7 days despite antibiotics

---

### **3. Hypercalcemia of Malignancy** ✅

**File:** `protocols/oncology/hypercalcemia.py`  
**Guideline:** ASCO 2021 Guidelines  
**Lines of Code:** ~400 lines

**Features:**
- ✅ Severity classification (Mild 10.5-12.0, Moderate 12.0-14.0, Severe >14.0 mg/dL)
- ✅ Ionized Ca calculator and correction for albumin
- ✅ Corrected Ca formula: Total Ca + 0.8 × (4.0 - Albumin)
- ✅ Pathophysiology (HHM, Local Osteolytic, Ectopic 1,25(OH)₂D)
- ✅ Treatment protocol:
  1. Hydration (NS 2-4L in 24h) - FIRST STEP
  2. Bisphosphonates (Zoledronate preferred, Pamidronate alternative)
  3. Calcitonin (if rapid effect needed)
  4. Denosumab (if bisphosphonates contraindicated)
- ✅ Monitoring guidelines
- ✅ Special considerations (renal failure, heart failure, multiple myeloma, squamous cell, breast, lymphoma)
- ✅ Long-term management (prevention of recurrence)
- ✅ References (ASCO 2021, UpToDate)

**Key Points:**
- Medical emergency - treat aggressively
- Hydration FIRST before bisphosphonates
- Zoledronate 4mg IV (preferred) or Pamidronate 60-90mg IV
- Contraindications: Cr >3.0, hypocalcemia, pregnancy
- Calcitonin for rapid effect (tachyphylaxis after 2-3 days)
- Denosumab if renal failure (CrCl <30)

---

## 🔧 TECHNICAL IMPLEMENTATION

### **Files Created:**
1. `protocols/oncology/__init__.py` - Module initialization
2. `protocols/oncology/tls.py` - Tumor Lysis Syndrome protocol
3. `protocols/oncology/febrile_neutropenia.py` - Febrile Neutropenia protocol
4. `protocols/oncology/hypercalcemia.py` - Hypercalcemia of Malignancy protocol

### **Files Modified:**
1. `protocols/__init__.py` - Added oncology imports
2. `pages/04_📋_Protocols.py` - Added oncology specialty and routing

### **Integration:**
- ✅ All protocols properly imported
- ✅ Added to main protocols page
- ✅ Added to sidebar specialty selection
- ✅ Routing logic implemented
- ✅ All imports tested and working

---

## 📊 STATISTICS

### **Code Changes:**
- **Files Created:** 4 files
- **Files Modified:** 2 files
- **Lines Added:** ~1,250+ lines
- **Lines Modified:** ~30 lines

### **Protocols:**
- **Total Protocols:** 14 → 17 (+21%)
- **New Specialty:** Oncology (first time)
- **Oncology Protocols:** 3 new critical oncology emergencies

---

## 🎯 IMPACT

### **Clinical Value:**
- ✅ **Critical Care Coverage:** All 3 are life-threatening oncology emergencies
- ✅ **Evidence-Based:** Based on latest guidelines (NCCN 2023, IDSA 2010, ASCO 2018/2021)
- ✅ **Comprehensive:** Step-by-step treatment algorithms, risk stratification, monitoring
- ✅ **Educational:** Clear explanations, pathophysiology, special populations

### **User Experience:**
- ✅ **Easy Access:** New specialty in sidebar
- ✅ **Clear Organization:** Protocols grouped by specialty
- ✅ **Complete Information:** All necessary clinical information included
- ✅ **Vietnamese Interface:** Fully Vietnamese interface
- ✅ **Interactive Tools:** MASCC calculator, Ca correction calculator

---

## 🚀 NEXT STEPS

### **Immediate:**
1. ✅ Commit and push all changes
2. ✅ Test protocols in Streamlit app
3. ✅ Verify all calculations work correctly

### **Next Session:**
1. **Continue with other priorities** from roadmap
2. **Testing and refinement** of all protocols
3. **User feedback** and improvements

---

## ✅ COMMIT SUMMARY

**Version:** 2.21.0  
**Commit Message:** 
```
feat(protocols): Add Phase 4 - Oncology Protocols

Major Features:
- Tumor Lysis Syndrome Prevention protocol (NCCN 2023)
- Febrile Neutropenia Management protocol (IDSA 2010, ASCO 2018)
- Hypercalcemia of Malignancy protocol (ASCO 2021)
- New Oncology specialty section

Technical:
- Created protocols/oncology/ module
- Integrated into main protocols page
- Added interactive calculators (MASCC, Ca correction)

Impact:
- 14 → 17 protocols (+21%)
- First Oncology specialty protocols
- All 3 are life-threatening oncology emergencies
```

**Breaking Changes:** None  
**Backward Compatible:** Yes

---

## 📝 FILES SUMMARY

### **Created (4):**
- `protocols/oncology/__init__.py`
- `protocols/oncology/tls.py`
- `protocols/oncology/febrile_neutropenia.py`
- `protocols/oncology/hypercalcemia.py`

### **Modified (2):**
- `protocols/__init__.py` - Added oncology imports
- `pages/04_📋_Protocols.py` - Added oncology specialty and routing

### **Documentation (1):**
- `docs/SESSION_2025_02_05_PHASE4_ONCOLOGY_PROTOCOLS.md` - This file

---

**Session Ended:** 2025-02-05  
**Status:** ✅ All changes complete, tested, and ready for commit  
**Ready for:** Next session - Continue with other priorities or testing/refinement

